The association of dietary energy density and the risk of obesity, type 2 diabetes and metabolic syndrome: a systematic review and meta‐analysis of observational studies

Author(s):  
Elham Bazshahi ◽  
Fatemeh Sheikhhossein ◽  
Mohammad Reza Amini ◽  
Sakineh Shab‐Bidar
Nutrition ◽  
2016 ◽  
Vol 32 (10) ◽  
pp. 1037-1047 ◽  
Author(s):  
Mohammad Hossein Rouhani ◽  
Fahimeh Haghighatdoost ◽  
Pamela J. Surkan ◽  
Leila Azadbakht

Author(s):  
Nasim Janbozorgi ◽  
Ramesh Allipour ◽  
Kurosh Djafarian ◽  
Sakineh Shab-Bidar ◽  
Mostafa Badeli ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. e027298
Author(s):  
Janett Barbaresko ◽  
Manuela Neuenschwander ◽  
Lukas Schwingshackl ◽  
Sabrina Schlesinger

IntroductionType 2 diabetes (T2D) is a major health concern associated with several comorbidities such as diabetic chronic kidney disease, neuropathy and cardiovascular diseases. Many of these complications may be preventable by an adequate lifestyle, including a favourable dietary behaviour, additionally to pharmacological management. In general, dietary guidelines for patients with diabetes recommend a hypocaloric diet to achieve a normal weight, but there is a lack of detailed instructions on specific nutrients and foods to prevent diabetes-related outcomes. Therefore, the aim of this systematic review and meta-analysis is to summarise the available evidence on the association between dietary factors and health-related outcomes in patients with T2D.Methods and analysisA systematic literature search will be conducted in PubMed and Web of Science in May 2019 to identify prospective observational studies investigating dietary factors in association with major complications in patients with T2D. We will include studies investigating dietary patterns, food groups, foods, macronutrients and micronutrients as well as secondary plant compounds. As diabetes-related outcomes, we will include macrovascular (cardiovascular and cerebrovascular diseases) and microvascular outcomes (nephropathy, neuropathy and retinopathy), as well as cancer, quality of life, depression, cognitive disorders and mortality. We will conduct dose-response meta-analyses using random effects models. We will investigate heterogeneity across studies and publication bias. To assess the risk of bias and quality of the included studies, we will use the Cochrane risk of bias tool ROBINS-I and the quality of evidence will be assessed using Grades of Recommendation, Assessment, Development, and Evaluation.Ethics and disseminationAs the systematic review is based on published studies, ethical considerations are not required. The systematic review and meta-analysis will be published in a peer-reviewed Journal.PROSPERO registration numberCRD42018110669


Sign in / Sign up

Export Citation Format

Share Document